| Business

Larger text Larger text Smaller text Smaller text | Order Photo Reprints

Merck, Pfizer sue to block proposed version of AzaSite

Email Newsletters

Click here to sign up for one of our email newsletters.

On the Grid

From the shale fields to the cooling towers, Trib Total Media covers the energy industry in Western Pennsylvania and beyond. For the latest news and views on gas, coal, electricity and more, check out On the Grid today.

MRK $47.80 -$0.15

PFE $29.16 +$0.07

MYL $31.54 -$0.14

at close on MONDAY

By Bloomberg News
Tuesday, June 18, 2013, 12:01 a.m.

Merck & Co. and Pfizer Inc. sued generic drugmaker Mylan Pharmaceuticals Inc. to block it from selling a copy of AzaSite, an antibiotic eye solution for fighting bacterial conjunctivitis.

Mylan told Pfizer, Merck and InSite Vision Inc. on May 1 that it sought Food and Drug Administration approval to sell a generic version of AzaSite, according to a lawsuit filed on Friday in federal court in Trenton, N.J. The complaint asks a judge to prevent Mylan from entering the market before the patents expire. One ends in 2018, and the other three expire in 2019, according to the FDA website.

Subscribe today! Click here for our subscription offers.



Show commenting policy

Most-Read Business Headlines

  1. Safety of credit cards up to banks
  2. Travelers love to hate cheap airlines
  3. Volkswagen may compensate vehicle owners for loss of value, CEO says
  4. Majority of House members sign petition calling for vote on Export-Import Bank’s charter
  5. Miata leaves cutesy behind for sleek
  6. 2 Fed members push case for rate hike in ’15
  7. ‘Coffin-nosed Cord’ was ahead of its time
  8. Uncle Charley’s Sausage expands sales to Maryland, Virginia
  9. UAW ups Fiat Chrysler workers’ pay in new proposal
  10. CMU showcases its lengthy list of fledgling companies at venture event
  11. Stocks wrap best week of year with slight gains